原研机构 |
非在研机构 |
权益机构- |
最高研发阶段临床1期 |
首次获批日期- |
最高研发阶段(中国)临床1期 |
特殊审评- |
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 系统性红斑狼疮 | 临床1期 | 中国 | 2024-07-20 | |
| 白血病 | 临床1期 | 中国 | 2022-08-22 | |
| 淋巴瘤 | 临床1期 | 中国 | 2022-08-22 | |
| 前体B细胞急性淋巴细胞白血病 | 临床1期 | 中国 | 2021-06-07 | |
| 复发性B细胞淋巴瘤 | 临床1期 | - | 2019-09-15 | |
| 难治性B细胞淋巴瘤 | 临床1期 | - | 2019-09-15 | |
| 弥漫性大B细胞淋巴瘤 | 临床1期 | 中国 | 2019-09-10 | |
| 边缘区B细胞淋巴瘤 | 临床1期 | 中国 | 2019-09-10 | |
| 抗中性粒细胞胞质抗体相关性血管炎 | 临床申请批准 | 中国 | 2025-06-10 | |
| B细胞白血病 | 临床申请 | 中国 | 2017-09-08 |
临床1期 | 6 | 艱廠鏇鏇鬱構鏇衊築憲(餘遞顧鬱範窪積簾餘獵) = All patients had grade I-II fever (drug-related) during the treatment. No other drug-related adverse events were observed including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome(ICANS), myelotoxicities, hypogammaglobulinemia or infections. 鬱衊鏇餘觸醖觸獵鹹夢 (鑰遞憲蓋觸糧餘範鬱鑰 ) | 积极 | 2024-11-10 | |||
临床1期 | 6 | 積憲廠夢繭遞淵繭繭簾(壓襯醖築觸顧衊遞鬱構) = All patients had grade I-II fever (drug-related) during the treatment. No other drug-related adverse events were observed. 淵簾淵膚膚壓糧淵壓鹽 (簾獵廠遞窪淵膚製鹽鏇 ) 更多 | 积极 | 2024-10-24 |






